Two chemotherapy regimens have been the standard for glioblastoma: temozolomide (Temodar) and the Gliadel Wafer (polifeprosan with carmustine implant). Temozolomide is an alkylating agent and alkylate/methylate DNA. This methylation damages the DNA and triggers the death of tumor cells. Gliadel Wafer is an implant for intracranial use, containing carmustine, a nitrosourea alkylating agent, and polifeprosan, a biodegradable copolymer used to control the release of carmustine.
Anti-angiogenesis agent bevacizumab (Avastin) is used as a second-line therapy for glioblastoma.
